Sterling Capital Management LLC Sells 1,085 Shares of United Therapeutics Corporation $UTHR

Sterling Capital Management LLC decreased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 43.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 1,429 shares of the biotechnology company’s stock after selling 1,085 shares during the period. Sterling Capital Management LLC’s holdings in United Therapeutics were worth $847,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Geneos Wealth Management Inc. increased its holdings in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares during the period. Jump Financial LLC bought a new stake in United Therapeutics during the 2nd quarter valued at $277,000. Cerity Partners LLC boosted its position in United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after acquiring an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia increased its holdings in shares of United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on UTHR shares. Bank of America boosted their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Cantor Fitzgerald lifted their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Royal Bank Of Canada reduced their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. HC Wainwright increased their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Finally, Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $619.42.

Insiders Place Their Bets

In related news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $541.55, for a total value of $4,494,865.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $24,462,896.60. This trade represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO James Edgemond sold 8,750 shares of United Therapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $538.15, for a total transaction of $4,708,812.50. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,158,119.40. This trade represents a 31.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 633,218 shares of company stock valued at $356,990,329. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Down 0.6%

Shares of UTHR opened at $541.83 on Wednesday. The firm has a market cap of $23.00 billion, a PE ratio of 20.00, a P/E/G ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The stock has a fifty day moving average price of $559.59 and a 200-day moving average price of $526.79.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter last year, the firm earned $6.63 earnings per share. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, research analysts forecast that United Therapeutics Corporation will post 26.63 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.